RxDoctor Payments Data

Gabriel Pantol, MD

Neurology · Wesley Chapel, FLNPI 1679733364

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,842 of the $50,536 with a category attached, or 67.0%. 60 manufacturers reported payments, led by AbbVie at 41.8% of the total. Reporting peaked in 2021 at $26,277 and has fallen 94.7% since, to $1,389 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,536in general payments, 2019–2025

Across 851 payments — averaging $59.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • AstraZeneca$3K
  • UCB, Inc.$1K
  • Biogen$867
  • plus $9K from 54 others
$13,940in research payments, 2019–2025

Across 6 payments — averaging $2323.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biohaven Pharmaceuticals, Inc.$11K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K

What the payments were for

  • Consulting fees$6001%
  • Speaking & faculty fees$33,84267%
  • Travel & lodging$8752%
  • Food & beverage$15,05930%
  • Education$1610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)197$21,139
Biohaven Pharmaceuticals, Inc.21$13,062
Biohaven Pharmaceutical Holding Company Ltd.19$2,643
AstraZeneca21$2,590
UCB, Inc.57$1,009
Biogen16$867
Novartis69$865
Teva Pharmaceuticals USA, Inc.69$835
Amgen(2 entities)33$737
Sanofi25$602
EMD Serono, Inc.25$555
Eisai Inc.16$357
CSL Behring16$328
Supernus Pharmaceuticals, Inc.49$327
Lilly USA, LLC14$264
Pfizer15$256
Jazz Pharmaceuticals Inc.10$240
Sunovion Pharmaceuticals Inc.15$236
Harmony Biosciences LLC10$233
Takeda Pharmaceuticals U.S.A., Inc.8$227
Acadia Pharmaceuticals Inc15$224
Acorda Therapeutics, Inc10$217
Genentech USA, Inc.13$215
SK Life Science, Inc.8$183
Avanir Pharmaceuticals, Inc.8$178
E.r. Squibb & Sons, L.L.C.4$152
Johnson & Johnson(2 entities)3$145
Gilead1$121
Neurelis, Inc.3$116
Portola Pharmaceuticals, LLC6$103
Penumbra, Inc.4$100
Catalyst Pharmaceuticals, Inc.4$94
TG Therapeutics, Inc.4$89
Adamas Pharmaceuticals, Inc.6$86
Bristol Myers Squibb4$81
Amneal Pharmaceuticals LLC4$80
Tanabe Pharma America, Inc.3$77
Sumitomo Pharma America, Inc.4$76
Aquestive Therapeutics, Inc.3$67
Lundbeck LLC3$63
Neurocrine Biosciences, Inc.4$62
Livanova USA, Inc.3$62
Kyowa Kirin, Inc.3$55
Medtronic3$51
MDD US Operations, LLC3$48
GE HealthCare2$42
Otsuka America Pharmaceutical, Inc.2$41
Greenwich Biosciences, Inc.2$40
Merz Pharmaceuticals, LLC2$37
Boston Scientific2$36
Argenx US, Inc.1$32
Grifols USA, LLC1$25
Microtransponder, Inc.1$25
Kedrion Biopharma, Inc.1$24
Vertical Pharmaceuticals, LLC1$22
Alnylam Pharmaceuticals Inc.1$22
Xeris Pharmaceuticals, Inc.1$21
Assertio Therapeutics, Inc.1$21
Collegium Pharmaceutical, Inc.1$19
Upsher-smith Laboratories LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,536 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$183,555
Medicare patients
517
Services billed
7,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$450,185
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$379,178
BotoxOnabotulinumtoxina30$42,340
Emgality PenGalcanezumab-Gnlm12$9,686
Pyridostigmine Bromide22$2,114
Carbidopa-LevodopaCarbidopa/Levodopa18$405
Baclofen13$391
Gabapentin20$239
Ropinirole Hcl13$226
Prednisone42$181
Pramipexole DihydrochloridePramipexole Di-Hcl17$172
Mirtazapine19$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$227$450,18526 claims
Grifols USA, LLCGamunex-C$25$379,17826 claims
AbbVieBotox$21,139$42,34030 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$80$2,11422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Wesley Chapel

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →